Evidence map›Paper›PMID 31849657›Full record

ArticleFrontiers in pharmacology2019

Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study.

Eline van Overbeeke, Rosanne Janssens, Chiara Whichello, Karin Schölin Bywall, Jenny Sharpe, Nikoletta Nikolenko, Berkeley S Phillips, Paolo Guiddi, Gabriella Pravettoni, Laura Vergani and 9 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 3 pooled it
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Do preferences differ based on respondent experience of a health issue and its treatment? A case study using a public health intervention.The European journal of health economics : HEPAC : health economics in prevention and care · 2023
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 6 countries.

Eline van OverbeekeClinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.
Rosanne JanssensClinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.
Chiara WhichelloSchool of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, Netherlands.
Karin Schölin BywallCentre for Research Ethics and Bioethics, Uppsala University, Uppsala, Sweden.
Jenny SharpeMuscular Dystrophy UK, London, United Kingdom.
Nikoletta NikolenkoJohn Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle, United Kingdom.
Berkeley S PhillipsPfizer, Tadworth, United Kingdom.
Paolo GuiddiApplied Research Division for Cognitive and Psychological Science, European Institute of Oncology, Milan, Italy.
Gabriella PravettoniApplied Research Division for Cognitive and Psychological Science, European Institute of Oncology, Milan, Italy.
Laura VerganiApplied Research Division for Cognitive and Psychological Science, European Institute of Oncology, Milan, Italy.
Giulia MartonApplied Research Division for Cognitive and Psychological Science, European Institute of Oncology, Milan, Italy.
Irina CleemputBelgian Health Care Knowledge Centre, Brussels, Belgium.
Steven SimoensClinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.
Jürgen KüblerQuantitative Scientific Consulting, Marburg, Germany.
Juhaeri JuhaeriSanofi, Bridgewater, NJ, United States.
Bennett LevitanJanssen Research & Development, Titusville, NJ, United States.
Esther W de Bekker-GrobSchool of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, Netherlands.
Jorien VeldwijkSchool of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, Netherlands.
Isabelle HuysClinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.
KU Leuven · BEErasmus University Rotterdam · NLEuropean Institute of Oncology · ITMuscular Dystrophy UK · GBUniversity of Milan · ITBelgian Health Care Knowledge Centre · BEJanssen (United States) · USPfizer (United Kingdom) · GBSanofi (United States) · USUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

decision-makinghealth technology assessmentmarketing authorizationmedical productspatient preferences

Identifiers

PMID31849657
PMCPMC6902285
OpenAlexW2994541683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.